ResMed Inc.
RMD · NYSE
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | -3.55 | 6.20 | 3.78 | 2.25 |
| FCF Yield | 1.03% | 1.34% | 1.69% | 0.86% |
| EV / EBITDA | 78.60 | 70.32 | 69.74 | 70.78 |
| Quality | ||||
| ROIC | 4.74% | 5.24% | 5.59% | 5.43% |
| Gross Margin | 61.46% | 60.84% | 59.33% | 58.60% |
| Cash Conversion Ratio | 1.31 | 1.42 | 1.59 | 0.90 |
| Growth | ||||
| Revenue 3-Year CAGR | 6.32% | 6.81% | 7.74% | 9.40% |
| Free Cash Flow Growth | -18.46% | -8.41% | 91.50% | -5.29% |
| Safety | ||||
| Net Debt / EBITDA | -1.07 | -0.67 | -0.20 | 0.66 |
| Interest Coverage | 50.78 | 0.00 | 0.00 | 87.14 |
| Efficiency | ||||
| Inventory Turnover | 0.54 | 0.57 | 0.61 | 0.60 |
| Cash Conversion Cycle | 183.30 | 176.88 | 175.12 | 179.58 |